Tirzepatide
Dual-action GLP-1/GIP agonist for metabolic health and weight management.
For research purposes only. These products are not intended to diagnose, treat, cure, or prevent any disease. By purchasing, you confirm these products will be used for legitimate research purposes.
About Tirzepatide
Tirzepatide is a first-in-class dual GLP-1 and GIP receptor agonist that provides superior glycemic control and weight reduction compared to single-agonist approaches. It activates both incretin pathways simultaneously, enhancing insulin secretion, slowing gastric emptying, and reducing appetite through complementary central and peripheral mechanisms.
Key Benefits
- Dual incretin receptor activation
- Superior appetite reduction
- Improved insulin sensitivity
- Enhanced glycemic control
Set a goal (top of the page) to see how Tirzepatide scores against it, and what the better-evidenced alternatives are.
Category Ratings
How to Take
Common Side Effects
- Nausea
- Diarrhea
- Decreased appetite
- Vomiting
- Constipation
- Abdominal pain
- Injection site reactions
- Risk of thyroid C-cell tumors (boxed warning)
Legal & Regulatory Status
Prescription required. FDA-approved: Mounjaro (type 2 diabetes) and Zepbound (obesity; obstructive sleep apnea in obesity). Carries a boxed warning for thyroid C-cell tumors.
Safety and regulatory details for FDA-approved compounds are drawn from the official product label via openFDA; clinical development status reflects ClinicalTrials.gov. This information is provided for research reference, is not endorsed by the FDA, and may not be complete or current.
Research & Sources
- FDA prescribing information — Mounjaro/Zepbound (tirzepatide), via DailyMed
- SURMOUNT-1: tirzepatide once weekly for obesity, NEJM (PMID 35658024)
Sources are selected for reliability (peer-reviewed literature, openFDA, ClinicalTrials.gov) but this is a research summary, not medical advice, and may not be exhaustive.